It is intended to provide a drug for improving prognosis for subarachnoid hemorrhage which contains, as the active ingredient, at least one member selected from the group consisting, of eicosapentaenoic acid (EPA) and pharmaceutically acceptable salts and esters thereof, and a method of improving prognosis for subarachnoid hemorrhage which comprises orally or gastrically administering the above drug.
